Alana Hippensteele, Senior Editor

The emergency use authorization is based on data from the EPIC-HR trial, which showed that the drug significantly reduced the risk of hospitalization or death compared with the placebo.

The drug is available in both oral suspension and tablet dosage forms for use in individuals aged 18 years or younger.

The drug is the first and only oral therapy approved for the treatment of adult patients who are candidates for either phototherapy or systemic therapy.

The agency’s approval follows trial results demonstrating the superior efficacy of the cabotegravir long-acting injectable to a daily oral PrEP option in reducing the risk of infection.

Data support daratumumab as part of a standard of care regimen in the frontline setting for patients with newly diagnosed multiple myeloma.

Patients with relapsed or refractory chronic lymphocytic leukemia are generally divided by those exposed to Bruton's tyrosine kinase inhibitors (BTKi), patients relapsing after venetoclax, and patients relapsing after BTKi and B-cell lymphoma-2 inhibitors.

Alterations in the amino acid profile of children with attention-deficit hyperactivity disorder may support further research into potential new treatment strategies.

The agents that have been evaluated and approved, and those that are coming in the pipeline, make for an exciting time to consider directed therapies.

New treatments show promise for patients with KRAS G12C–mutated disease.

The FDA approved pembrolizumab plus lenvatinib for the first-line treatment of adult patients with advanced RCC.

Erenumab was found to have a sustained efficacy as a monotherapy treatment for episodic migraine that was found to not respond to 2 to 4 prior preventive treatments.